# Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome

Source: https://onco.cc/trials/nct04920149/  
OnCo record `nct04920149` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial in colorectal cancer, run by Ann-Sofie Backman, now recruiting.

## Summary

Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome is a phase 2, randomised interventional study registered as NCT04920149 by Ann-Sofie Backman, with a registry enrolment figure of 150 participants, started 2022-03-21 and due to reach its primary completion in 2032-09-30. Interventions recorded: Mesalamine; Placebo. Conditions listed: Lynch Syndrome; Colon Cancer; Colon Neoplasm. Primary outcome: Change in the occurrence of any colorectal neoplasia in LS patients; Change in the occurrence of any colorectal neoplasia in LS patients. Colorectal eligibility wording from the registry: "* Presence of colorectal endoscopically non-removable benign neoplasia (patient can be included if the adenoma is removed)". Sites: Denmark, Sweden. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: MesaCAPP
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT04920149
- Phase: 2
- Setting: Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome
- Sponsor: Ann-Sofie Backman
- Enrolled: 150

## Sources

- ClinicalTrials.gov NCT04920149: https://clinicaltrials.gov/study/NCT04920149

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Mismatch-repair deficient (MSI-high) colorectal cancer](https://onco.cc/cancers/msi-high-colorectal/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct04920149.json